z-logo
open-access-imgOpen Access
Intranasal Oxytocin in Children and Adolescents with Autism Spectrum Disorder
Author(s) -
Linmarie Sikich,
Alexander Kolevzon,
Bryan H. King,
Christopher J. McDougle,
Kevin Sanders,
Soojeong Kim,
Marina Spanos,
Tara Chandrasekhar,
Maria del Pilar Trelles,
Carol Rockhill,
Michelle Palumbo,
Allyson Witters Cundiff,
Alicia Montgomery,
Paige M. Siper,
Mendy Minjarez,
Lisa A. Nowinski,
Sarah Marler,
Lauren C. Shuffrey,
Cheryl Alderman,
Jordana Weissman,
Brooke Zappone,
Jennifer Mullett,
Hope Crosson,
Natalie Hong,
Stephen K. Siecinski,
Stephanie N. Giamberardino,
Sheng Luo,
Lilin She,
Manjushri Bhapkar,
Russell Dean,
Abby Scheer,
Jacqueline L. Johnson,
Simon G. Gregory,
Jeremy VeenstraVanderWeele
Publication year - 2021
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa2103583
Subject(s) - oxytocin , autism spectrum disorder , autism , nasal administration , psychology , clinical trial , spectrum disorder , clinical psychology , medicine , psychiatry , neuroscience , pharmacology
Experimental studies and small clinical trials have suggested that treatment with intranasal oxytocin may reduce social impairment in persons with autism spectrum disorder. Oxytocin has been administered in clinical practice to many children with autism spectrum disorder.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom